MAI Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

MAI Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$3.07K	–	1155
2023 Q3	$3.07K	Sell	4 -218	-98%	-$935K	﹤0.01%	1048
2023 Q2	$1.02M	Sell	222 -20	-8%	-$69.4K	0.02%	426
2023 Q1	$641K	Sell	242 -24	-9%	-$70.3K	0.01%	554
2022 Q4	$694K	Sell	266 -55	-17%	-$192K	0.01%	516
2022 Q3	$1.27M	Buy	321 +189	+143%	+$743K	0.02%	331
2022 Q2	$345K	Buy	+132	New	+$344K	0.01%	651

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAI Capital Management's SEEL Position: Q4 2023 in Review

MAI Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 4 shares — an estimated $3.07K sold.

MAI Capital Management first reported a position in SEEL in Q2 2022 and held it in 6 quarters. The position peaked at $1.27M in Q3 2022. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

MAI Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
MAI Capital Management sold 4 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.07K.
MAI Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
MAI Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $1.27M in Q3 2022.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on MAI Capital Management's 13F filing for Q4 2023, filed 9 Feb 2024.